Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Candida Systemic Clear all
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia

NCT03604705
View directory record Official record
Conditions
Candidemia
Interventions
APX001
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Davis, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 22, 2026, 4:04 PM EDT
Completed No phase listed Observational

Serial Therapeutic and Antifungal Monitoring Protocol

NCT02163889
View directory record Official record
Conditions
Candidemia
Interventions
Not listed
Lead sponsor
T2 Biosystems
Industry
Eligibility
18 Years to 95 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Jul 22, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

NCT03667690
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions
Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Jul 22, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

NCT02734862
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis
Interventions
CD101, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Davis, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Jul 22, 2026, 4:04 PM EDT
Completed Phase 4 Interventional Results available

Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis

NCT00496197
View directory record Official record
Conditions
Candidiasis
Interventions
Eraxis (anidulafungin), Diflucan (fluconazole), Vfend (voriconazole)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2011 · Synced Jul 22, 2026, 4:04 PM EDT
Completed No phase listed Observational

Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)

NCT01525095
View directory record Official record
Conditions
Candidemia
Interventions
Not listed
Lead sponsor
T2 Biosystems
Industry
Eligibility
18 Years to 95 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Birmingham, Alabama • San Francisco, California • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Jul 22, 2026, 4:04 PM EDT
Completed No phase listed Observational

PEACE: Pediatric Antifungal Comparative Effectiveness

NCT01869829
View directory record Official record
Conditions
Pediatric Invasive Candidiasis
Interventions
Observational antifungal therapy
Drug
Lead sponsor
Duke University
Other
Eligibility
120 Days to 18 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
27
States / cities
Little Rock, Arkansas • Orange, California • Palo Alto, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Jul 22, 2026, 4:04 PM EDT
Completed No phase listed Observational

BIOPIC: Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric Candidemia

NCT02220790
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
120 Days to 18 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
19
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Jul 22, 2026, 4:04 PM EDT
Completed Phase 3 Interventional

Anidulafungin Versus Fluconazole in the Treatment of Candidemia

NCT00058682
View directory record Official record
Conditions
Candida, Candidiasis
Interventions
Anidulafungin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

NCT03059992
View directory record Official record
Conditions
Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis, Blastomycosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Invasive Pulmonary Aspergillosis, Recurrent Vulvovaginal Candidiasis, Other Emerging Fungi
Interventions
Ibrexafungerp
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Jul 22, 2026, 4:04 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Micafungin in Children on Extracorporeal Membrane Oxygenation

NCT01666769
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
Micafungin
Drug
Lead sponsor
Kevin Watt
Other
Eligibility
Up to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Jul 22, 2026, 4:04 PM EDT
Completed Phase 1 Interventional

Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

NCT00608335
View directory record Official record
Conditions
Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis, Esophageal Candidiasis
Interventions
Micafungin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
2 Years to 16 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Jul 22, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)

NCT03363841
View directory record Official record
Conditions
Candidiasis, Invasive, Candidemia
Interventions
SCY-078
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Jersey City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jul 22, 2026, 4:04 PM EDT
Completed Phase 4 Interventional Results available

Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)

NCT00520234
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
Caspofungin, Normal Saline
Drug
Lead sponsor
Mycoses Study Group
Network
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 8, 2011 · Synced Jul 22, 2026, 4:04 PM EDT
Recruiting Not applicable Interventional

Comparison of Uncomplicated Candidemia Therapy Duration in Children

NCT05763251
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
therapy duration
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
120 Days and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
21
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 22, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

NCT02244606
View directory record Official record
Conditions
Mycoses, Candidiasis, Invasive, Candidemia
Interventions
SCY-078, Fluconazole, Micafungin
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Birmingham, Alabama • Sacramento, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Jul 22, 2026, 4:04 PM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.

NCT00037219
View directory record Official record
Conditions
Candidiasis
Interventions
Anidulafungin, VER002
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Jul 22, 2026, 4:04 PM EDT
Completed Not applicable Interventional Results available

β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients

NCT00672841
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
Preemptive Therapy with Anidulafungin, Empiric antifungal therapy based on physician discretion.
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Jul 22, 2026, 4:04 PM EDT
Completed Phase 3 Interventional

Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units

NCT00099775
View directory record Official record
Conditions
Candidiasis
Interventions
Caspofungin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 4:04 PM EDT
Terminated Phase 3 Interventional Results available

Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis

NCT00815516
View directory record Official record
Conditions
Candidiasis
Interventions
micafungin, amphotericin B deoxycholate
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
48 Hours to 120 Days
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Orange, California • New Brunswick, New Jersey • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Jul 22, 2026, 4:04 PM EDT
Terminated Phase 3 Interventional

Caspofungin Study for Fungal Infections in Adults in Critical Care Settings

NCT00095316
View directory record Official record
Conditions
Candidiasis
Interventions
Caspofungin, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Jul 22, 2026, 4:04 PM EDT
Terminated Phase 3 Interventional Results available

An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida

NCT00805740
View directory record Official record
Conditions
Candidiasis, Fungemia
Interventions
Active anidulafungin, Active Caspofungin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Newark, Delaware • Wilmington, Delaware • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Jul 22, 2026, 4:04 PM EDT
Completed Phase 3 Interventional

The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis

NCT00056368
View directory record Official record
Conditions
Candidiasis
Interventions
Anidulafungin, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Jul 22, 2026, 4:04 PM EDT
Completed Not applicable Interventional

Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants

NCT00113191
View directory record Official record
Conditions
Nosocomial Infections, Sepsis, Staphylococcal Infections, Candidemia
Interventions
Veronate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
3 Days to 5 Days
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
85
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 71 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Jul 22, 2026, 4:04 PM EDT